Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: A multicenter cluster randomized controlled trial (ENGAGE). by Livingston, PM et al.
Effects of a Clinician Referral and Exercise Program for Men
Who Have Completed Active Treatment for Prostate Cancer: A
Multicenter Cluster Randomized Controlled Trial (ENGAGE)
Patricia M. Livingston, PhD1; Melinda J. Craike, PhD2; Jo Salmon, PhD3; Kerry S. Courneya, PhD4; Cadeyrn J. Gaskin, PhD2;
Steve F. Fraser, PhD3; Mohammadreza Mohebbi, PhD1; Suzanne Broadbent, PhD5; Mari Botti, PhD6; Bridie Kent, PhD7;
and the ENGAGE Uro-Oncology Clinicians’ Group
BACKGROUND: The purpose of this study was to determine the efficacy of a clinician referral and exercise program in improving
exercise levels and quality of life for men with prostate cancer. METHODS: This was a multicenter cluster randomized controlled trial
in Melbourne, Australia comprising 15 clinicians: 8 clinicians were randomized to refer eligible participants (n554) to a 12-week exer-
cise program comprising 2 supervised gym sessions and 1 home-based session per week, and 7 clinicians were randomized to follow
usual care (n593). The primary outcome was self-reported physical activity; the secondary outcomes were quality of life, anxiety,
and symptoms of depression. RESULTS: A significant intervention effect was observed for vigorous-intensity exercise (effect size:
Cohen’s d, 0.46; 95% confidence interval [CI], 0.09-0.82; P5.010) but not for combined moderate and vigorous exercise levels (effect
size: d, 0.08; 95% CI, 20.28 to 0.45; P5.48). Significant intervention effects were also observed for meeting exercise guidelines (150
min/wk; odds ratio, 3.9; 95% CI, 1.9-7.8; P5.002); positive intervention effects were observed in the intervention group for cognitive
functioning (effect size: d, 0.34; 95% CI, 20.02 to 0.70; P5.06) and depression symptoms (effect size: d, 20.35; 95% CI, 20.71 to
0.02; P5.06). Eighty percent of participants reported that the clinician’s referral influenced their decision to participate in the exer-
cise program. CONCLUSIONS: The clinician referral and 12-week exercise program significantly improved vigorous exercise levels and
had a positive impact on mental health outcomes for men living with prostate cancer. Further research is needed to determine the
sustainability of the exercise program and its generalizability to other cancer populations. Cancer 2015;121:2646-54. VC 2015 The
Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the
terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited and is not used for commercial purposes.
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INTRODUCTION
Prostate cancer is the most commonly diagnosed male cancer in developed countries (with nonmelanoma skin cancer
excluded)1 and accounts for approximately 30% of cancers diagnosed each year in Australian men.2
Across the disease trajectory, men living with prostate cancer have complex physical and psychological needs and
subsequent long-term morbidity, with reduced functional capacity, decreased symptom control, and poorer quality-of-
life outcomes.3-7
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Exercise can have a positive impact on clinical out-
comes in men with prostate cancer and has been shown to
improve physiological and psychological outcomes by
reducing treatment-related toxicities, preventing second-
ary comorbidities, enhancing functional capacity, and
improving an individual’s quality of life.8-13 However,
many men with prostate cancer do not participate in regu-
lar exercise. Increasing age, comorbid conditions, cancer
stage, side effects of treatment, and limited access to tar-
geted programs and facilities have been identified as fac-
tors that influence participation in exercise for men living
with the condition.8-12 Furthermore, men lack the confi-
dence in their ability to be physically active and do not
have knowledge about appropriate exercise levels.12,14,15
Addressing barriers to exercise participation requires
a multipronged approach. One strategy is for clinicians to
encourage exercise as part of patients’ clinical care through
a referral to an exercise program that is tailored to individ-
ual capabilities. Research has highlighted the importance
of cancer clinician endorsement of physical activity rec-
ommendations to improving physical activity levels in
men with prostate cancer,12 with cancer survivors increas-
ingly looking for lifestyle advice, such as exercise, to
improve their health outcomes.14 A recent study of men
with prostate cancer suggested that encouragement from
clinicians and referral to an exercise specialist were likely
to give men more confidence to participate in physical ac-
tivity.12 However, the effectiveness of this approach has
not been tested because exercise programs do not form
part of standard clinical care after a cancer diagnosis.16
Few clinicians view their role as health promotion advo-
cates, with only 20% promoting lifestyle changes to their
patients.17 A recent survey of clinicians who treated men
with prostate cancer showed that more than half of clini-
cians (55%) reported that advising patients on physical ac-
tivity was not part of their role, with “not enough time”
and a “lack of knowledge/resources” being the most com-
mon barriers to promoting physical activity.18
The development of clinical partnerships and refer-
ral pathways with allied health personnel, such as exercise
physiologists, could overcome the barriers experienced by
clinicians. Such referrals would allow men with prostate
cancer to receive an appropriate exercise dose to optimize
therapeutic outcomes while receiving endorsement from
their trusted treating clinicians.7
Study Aims and Hypotheses
The primary aim of this study was to assess the efficacy of a
clinician-referred 12-week exercise program in comparison
with usual care in increasing self-reported physical activity
levels for men who had completed active treatment for
prostate cancer. Secondary aims examined the effect of the
exercise program on psychological well-being, quality of
life, and objectively assessed physical activity. We hypothe-
sized that participants in the intervention would be more
physically active and have improved quality of life in com-
parison with participants in the control condition.
MATERIALS AND METHODS
Study Design
The study was a 2-armed, prospective, multicenter cluster
randomized controlled trial evaluating the effects of a
medical or nursing clinician referral to a 12-week exercise
program (comprising 2 gym sessions and 1 home-based
session per week and commencing 3 to 12 months after
active treatment for prostate cancer) in comparison with
usual care. The study was approved by the institutional
research ethics committee. A detailed description of the
study methods is available in the published protocol.19
Random Assignment
Fifteen clinicians (71%) who agreed to participate in the
study were randomly allocated with an online random
number generator to either the intervention (n5 8) or the
control condition (n5 7). Clinicians remained in the 1
randomized condition for the entire recruitment period.
Intervention clinicians were trained in the referral process,
which comprised a standard script to follow and a referral
slip19 to the supervised exercise program, which was
handed to the participant during the consultation, as part
of the standardized procedure.
Participant Recruitment
Recruitment occurred through urology and radiation on-
cology outpatient clinics across 3 major public health serv-
ices and 4 private clinics located across Melbourne,
Australia. Men were eligible to participate if they had
completed active treatment for prostate cancer within the
previous 3 to 12 months, were treated with curative
intent, and could complete surveys in the English lan-
guage. Men on hormone treatment were also eligible to
take part in the study. Before a patient’s consultation with
a clinician at an outpatient clinic, eligible patients were
informed about the study, provided with an information
package, and followed up with respect to their interest in
participating in the study. Those who were interested
were asked to sign and return the consent form and base-
line questionnaire before their participation in the study.
During the consultation, clinicians randomized to
the intervention condition provided a standardized
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referral slip,19 which stated that the participant had been
assigned to the exercise group and that the clinician rec-
ommended that they participate in the exercise program.
Clinicians randomized into the control condition pro-
vided usual care regarding physical activity advice, which
was typically minimal information. Clinician adherence
to the study process was monitored each week.
The supervised exercise program was undertaken at
each participant’s local community gym and was supervised
by exercise physiologists. The 12-week exercise programwas
based on exercise guidelines for cancer survivors developed
by the American College of Sports Medicine20 and Exercise
and Sport Science Australia21 and was guided by social cog-
nitive theory.22 Postgraduate clinical exercise physiology
students under the supervision of accredited exercise physi-
ologists instructed participants during 2 supervised, 50-
minute sessions per week at local gym facilities, and they
advised participants on a weekly home-based session.
The primary outcome was the number of self-
reported minutes of moderate-vigorous physical activity
(MVPA) per week as measured with an adapted Godin-
Shepherd Leisure Time Exercise Questionnaire, which
was administered to assess participation in physical activ-
ity.23 Participants were asked to recall their average weekly
frequency and duration of light-intensity activity (mini-
mal effort, no perspiration), moderate-intensity activity
(not exhausting, light perspiration), and vigorous-
intensity activity (rapidly beating heart, sweating) in a typ-
ical week in the past month. We also calculated the per-
centage of participants meeting aerobic exercise guidelines
of combined MVPA levels 150 min/wk and the num-
ber who reported zeroMVPA levels.
The secondary outcomes included an objective
assessment of physical activity as well as self-reported
depressive symptoms, anxiety, and quality of life. All par-
ticipants were asked to wear a hip-mounted accelerometer
(GT1M; ActiGraph, Pensacola, FL) for 7 days at the base-
line and immediately after the 12-week exercise program
(equivalent time period for the control group) to obtain a
quantitative measure of light-intensity activity and
MVPA on an average day according to the Freedson adult
cut points.24 Accelerometry data were processed with
ActiLife software (version 6.7.1) and managed with a cus-
tomized Excel macro. Minutes of daily light-intensity ac-
tivity and MVPA were calculated by the summation of
valid days (10 hours of wear time per day, with the re-
moval of 60 minutes of consecutive zero counts),
weighted by week and weekend days and divided by 7.
Quality of life was measured with the European Organiza-
tion for Research and Treatment of Cancer core quality-
of-life questionnaire (QLQ-C30, version 3) and prostate
tumor–specific module (QLQ-PR25).25 Prostate cancer–
related anxiety was measured with the Memorial Anxiety
Scale for Prostate Cancer (MAX-PC).26 Depressive symp-
toms were assessed with the 20-item Center for Epidemio-
logical Studies Depression Inventory, with mean and total
scores calculated.27
A satisfaction survey (intervention group) was con-
ducted to assess the acceptability and feasibility of the cli-
nician referral and exercise program. Participants were
asked a series of questions about how much the clinician
referral influenced their decision to participate in the 12-
week program and their experience with the 12-week pro-
gram, including whether they met their exercise goals,
whether the gym location was convenient, and whether
they intended to continue the exercise program after the
study was completed.
Data Analysis
t tests and chi-square tests were used to compare baseline
characteristics between the intervention and control
groups. To assess the impact of the intervention on pri-
mary and secondary outcomes, time-by-treatment interac-
tions were analyzed in a repeated measures split plot in
time analysis of variance model for continuous outcomes.
Post hoc contrasts were also conducted to determine
follow-up by intervention impact. Repeated measures
logistic regression was used for binary outcomes to evalu-
ate time-by-treatment interactions. In both scenarios,
model parameters were estimated with generalized esti-
mating equations with an exchangeable working correla-
tion matrix to take account of the repeated measures for
each participant. Effect sizes (follow-up by intervention
effect) were calculated with Cohen’s d. Odds ratios were
transformed into effect sizes with a logarithmic transfor-
mation.28 We performed an intention-to-treat analysis
with a linear mixed model approach. Tests were 2-tailed
with the statistical significance set at an a level of .05.
The analyses were undertaken with STATA.
RESULTS
A consecutive series of men who completed active treat-
ment for prostate cancer was screened from October
2011 to June 2013. In all, 741 patients were screened,
and 443 (60%) met the eligibility criteria; 320 of these
patients (72%) were approached, and 147 (46%) partici-
pated (Fig. 1). Participant compliance with questionnaire
completion was very high; 95% completed each of the 2
time points, with minimal missing data for the primary
and secondary outcomes (<1%). The overall attrition
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Figure 1. Consort diagram showing recruitment of patients into the ENGAGE study.
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rate was 12% (control group, 11%; intervention group,
13%; P5 .70).
Participants ranged in age from 39 to 84 years
(mean, 65.6 years; standard deviation, 8.5 years); the ma-
jority had stage I or II disease. At baseline, there were no
significant differences in patient demographics or exercise
levels. A statistically significant difference was observed,
however, in stage of disease and treatment regimens
between the 2 groups (Table 1).
For those who completed the supervised program,
85% of participants adhered to at least 18 of the 24 gym-
based sessions (median, 88%; interquartile range, 17%).
Among those who completed their home exercise diary (40
of 54 or 74%), an average of 81% (median, 88%; inter-
quartile range, 17%) completed 9 to 12 of the prescribed
home-based weekly sessions.
There were no significant intervention effects on
MVPA (intervention impact, 33 minutes; effect size: d,
0.08; 95% confidence interval [CI], 20.28 to 0.45;
P5 .48; Table 2 and Fig. 2); however, significant inter-
vention effects were observed for vigorous exercise (inter-
vention impact: 45 minutes; effect size: d, 0.46; 95% CI,
0.09-0.82; P5 .010). Significant intervention effects
were observed for the percentage meeting aerobic exercise
guidelines of combined MVPA levels 150 min/wk
(odds ratio, 3.9; 95% CI, 1.9-7.8; P5 .002; effect size: d,
0.75; 95%CI, 0.35-1.13; Table 3 and Fig. 2). At baseline,
48% of participants in the control condition (minimum,
0 mins; maximum, 1260 mins) and 41.5% in the inter-
vention group (minimum, 0 mins; maximum, 1620
mins) reported zero MVPA (P5 .43). At follow-up, 3
participants (6%) reported zero MVPA in the interven-
tion group (minimum, 0 mins; maximum, 1500 mins),
whereas 30 (32%) did in the control condition (mini-
mum, 0 mins; maximum, 1560 mins; P5 .0001; odds
ratio, 4.8; 95%CI, 1.60-14.20).
There were no significant differences between
groups in objectively (accelerometer) assessed MVPA
minutes on an average day (Table 3).
TABLE 1. Demographic and Clinical Characteristics
of Participants in the ENGAGE Trial at Baseline by
Condition
Characteristics Control Intervention P
Demographics
Age, mean (SD), years 64.7 (8.7) 66.9 (8.2) .69
Body mass index, mean (SD), kg/m2 28.0 (3.8) 28.0 (3.5) .97
Marital status, No. (%) .31
Married/living with a partner 69 (78.4) 45 (83.3)
Not married/living with a partner 19 (21.6) 9 (16.7)
Education status, No. (%) .85
Primary 6 (6.7) 3 (5.7)
Secondary 31 (34.4) 15 (28.3)
Certificate/diploma 30 (33.3) 19 (35.9)
University 23 (25.6) 16 (30.1)
Private health service 25 (26.9) 14 (25.9) .90
MVPA combined, mean (SD), min/wk 104.3 (18.4) 167.7 (41.0) .11
VPA, mean (SD), min/wk 25.7 (11.5) 33.3 (11.7) .66
Moderate physical activity,
mean (SD), min/wk
78.6 (12.2) 134.4 (34.6) .08
Exercising 150 min/wk, No. (%) 15 (28.6) 33 (35.8) .36
Inactive participants
(0 min/wk of MVPA), No. (%)
44 (48.4) 22 (41.5) .43
Clinical data
Staging of disease, No. (%) .01
I 28 (35) 20 (48)
II 42 (52.5) 11 (26)
III 10 (12.5) 11 (26)
Weeks since active
treatment, mean (SD)
25 (9.19) 25 (11.39) .89
Treatment regimen, No. (%) .03
Surgery only 46 (49.5) 18 (33.3)
Surgery and radiotherapy 16 (17.2) 15 (27.8)
Surgery, radiotherapy, and ADT 5 (5.4) 3 (5.5)
Radiotherapy only 16 (17.2) 5 (9.3)
Radiotherapy and ADT 8 (8.6) 13 (24.1)
Surgery and ADT 2 (2.1) 0 (0)
Abbreviations: ADT, androgen-deprivation therapy; MVPA, moderate-
vigorous physical activity; SD, standard deviation; VPA, vigorous physical
activity.
TABLE 2. Primary Outcome Measures (Self-Reported Physical Activity) for Intervention and Control Partici-
pants at Baseline and the 12-Week Follow-Up
Physical Activity, Mean (SD), min/wk
Effect Measure
Effect Size:
Cohen’s d (95% CI)
Control Intervention
Baseline Follow-Up Baseline Follow-Up
Follow-Up by
Intervention P
Follow-Up by
Intervention
Effect (95% CI)a
Moderate-vigorous
activity combined
104 (176) 153 (237) 168 (298) 252 (261.7) .48 33 (259 to 126) 0.08 (20.28 to 0.45)
Vigorous-intensity activity 26 (110) 42 (151) 33 (85) 94 (117) .01 45 (11-79) 0.46 (0.09-0.82)
Moderate-intensity activity 79 (116) 111 (169) 134 (252) 162 (254) .90 26 (294 to 82) 20.03 (20.40 to 0.33)
Abbreviations: CI, confidence interval; SD, standard deviation.
a Post hoc intervention by follow-up interaction contrast.
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Borderline intervention effects were observed for the
cognitive functioning subscale of the QLQ-C30 (effect
size: d, 0.34, 95%CI,20.02 to 0.70; P5 .06) and Center
for Epidemiological Studies Depression Inventory depres-
sion symptoms (effect size: d, 20.35; 95% CI, 20.71 to
0.02; P5 .06). There was a significant decrease in total
anxiety in the control group versus the intervention group
(effect size: d, 0.42; 95%CI, 0.06-0.79; P5 .02).
Forty-seven participants (87%) completed the inter-
vention evaluation. Eighty percent of those participants
reported that the clinician’s referral influenced their deci-
sion to participate in the exercise program; 75% reported
that they would recommend the exercise program to other
people living with prostate cancer; 91.5% reported that
the exercise program was rewarding; 94% reported that
participating in the 12-week exercise program was
extremely or quite useful; 88% reported that the program
was extremely or quite beneficial to their health and well-
being; 83% reported that they achieved their exercise
goals; 79% reported that the location of the gym was con-
venient; and 45% reported an intention to continue with
the physical activity program by joining a gym in the com-
ing month.
Figure 2. Effect sizes (95% confidence intervals) of physical
activity levels for minutes of physical activity per week and
for physical activity 150 min/wk.
TABLE 3. Secondary Outcome Measures for Intervention and Control Participants at Baseline and the 12-
Week Follow-Up
Control Intervention Effect Measure
Effect Size:
Cohen’s d
(95% CI)
Baseline
n591
Follow-Up
n5 83
Baseline
n5 53
Follow-Up
n5 46
Follow-Up by
Intervention P
Follow-Up by
Intervention
OR (95% CI)a
MVPA 150 min/wk, % 28.6 43.4 35.8 69.6 .002 3.9 (1.9-7.8) 0.75 (0.35-1.13)
Control Intervention Effect Size:
Cohen’s d
(95% CI)
Baseline Follow-Up Baseline Follow-Up Follow-Up by
Intervention P
Intervention
Interaction
Impact Effect
(95% CI)
Accelerometer, mean (SD),
min/day
n5 48 n539 n544 n5 31
MVPA 38 (22) 36 (23) 40 (20.9) 33 (16.5) .31 24.5 (213.1 to 4.2) 0.17 (20.33 to 0.67)
Vigorous intensity 2 (12) 0.6 (2) 1 (4) 1.5 (4) .38 21.8 (22.13 to 5.67) 20.18 (20.68 to 0.32)
Moderate intensity 36 (19) 36 (22) 39 (20) 31 (16) .11 5.9 (213.3 to 1.4) 0.33 (20.17 to 0.83)
Quality of life (EORTC-30),
mean, SD
n5 91 n583 n553 n5 47
Physical 91.9 (11.4) 94.3 (10.2) 91.6 (10.6) 94.5 (9.2) .83 0.3 (22.3 to 2.9) 0.02 (20.3 to 0.4)
Cognitive 85.2 (17.5) 86.7 (16.8) 83.3 (17.9) 89.0 (16.8) .06 4.0 (20.2 to 8.2) 0.34 (20.02 to 0.7)
Emotional 83.0 (21.3) 88.4 (17.4) 86.5 (17.8) 88.7 (15.6) .14 24.03 (29.40 to 1.33) 20.3 (20.67 to 0.06)
Social 85.0 (24.2) 90.0 (19.3) 84.3 (21.0) 92.9 (13.3) .45 3.1 (24.9 to 11.2) 0.08 (20.3 to 0.4)
Role Functioning 89.7 (22.9) 93.0 (17.5) 88.7 (19.3) 94.7 (13.1) .65 1.6 (25.2 to 8.4) 0.02 (20.3 to 0.4)
Global 77.5 (16.0) 80.0 (15.9) 75.9 (17.4) 80.3 (14.7) .37 2.2 (22.6 to 6.9) 0.2 (20.2 to 0.5)
Anxiety (MAX-PC), mean (SD) n5 91 n582 n553 n5 47
Total score 12.7 (11.1) 9.8 (9.6) 9.1 (8.3) 8.7 (8.8) .02 2.48 (0.37-4.58) 0.42 (0.06-0.79)
Prostate cancer
anxiety (subscale 1)
7.9 (8.6) 5.9 (7.4) 5.5 (6.3) 3.9 (6.3) .64 0.40 (21.29 to 2.10) 0.08 (20.28 to 0.44)
PSA anxiety (subscale 2) 0.6 (1.2) 0.2 (0.7) 0.1 (0.6) 0.2 (1.2) .03 0.43 (0.04-0.83) 0.38 (20.01 to 0.74)
Fear of recurrence
anxiety (subscale 3)
4.2 (3.3) 3.8 (3.3) 3.5 (3.1) 4.5 (4.2) .01 1.6 (0.27-2.93) 0.45 (0.08-0.81)
Depression (CES-D), mean (SD) n5 91 n583 n553 n5 47
Depression symptoms 8.5 (7.0) 7.6 (6.9) 8.9 (9.3) 6.5 (7.6) .06 21.83 (23.79 to 0.13) 20.35 (20.71 to 0.02)
Abbreviations: CES-D, Center for Epidemiological Studies Depression Inventory; CI, confidence interval; EORTC-30, European Organization for Research and
Treatment of Cancer 30; MAX-PC, Memorial Anxiety Scale for Prostate Cancer; MVPA, moderate-vigorous physical activity; OR, odds ratio; PSA, prostate-
specific antigen; SD, standard deviation.
aPost hoc intervention by follow-up interaction contrast.
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DISCUSSION
This study involved a multipronged approach to improv-
ing exercise outcomes among men living with prostate
cancer that included a standardized clinician referral to a
supervised exercise program. Compared with men in the
control condition, men in the intervention condition
undertook more than twice as much vigorous exercise at
follow-up and had almost 4 times the odds of meeting
exercise guidelines (150 min/wk of MVPA) and nearly
5 times the odds of avoiding complete inactivity (0
MVPA minutes). However, the failure of our exercise
intervention to significantly improveMVPAminutes may
in part be due to the variation in the 2 groups both at base-
line and at follow-up, which resulted in imprecise interval
estimations. For example, 48% of those in the control
condition and 41.5% in the intervention group did not
participate in MVPA at the baseline, and this inflated the
variance; at follow-up, 32% in the control group reported
zeroMVPA, whereas only 6% in the intervention group.
There were no significant intervention effects based
on objectively measured physical activity. This may be
due to the limited ability of the device to capture activities
such as swimming, biking, and strength training29 or due
to behavioral compensation in total daily physical activity
(as reflected by the device’s ability to capture all major
bodily movement in comparison with the self-report
measure, which is based mainly on structured activities)
or the timing of wearing the accelerometer (ie, in the week
immediately before and after the intervention).
The intervention did produce positive findings for
depressive symptoms and quality-of-life outcomes (specif-
ically improved cognitive function). The importance of
exercise in improving quality-of-life outcomes has been
supported by recently published Cochrane reviews and
meta-analyses. However, because only 12% of the partici-
pants in the current study had clinical depression (16) at
baseline, our ability to determine a significant impact of
the program on depressive symptoms was limited. Cogni-
tive dysfunction is a common outcome for men with pros-
tate cancer and particularly for those on androgen-
deprivation therapy. Regular exercise improves cardiovas-
cular fitness, which has a positive association with cogni-
tive performance in older adults and a protective effect
against cognitive decline.30 There are several potential
mechanisms explaining these associations: vascular contri-
butions from exercise may delay or prevent the onset of
cerebrovascular disease, exercise increases the expression
of synaptic plasticity genes and results in increased brain
neuroplasticity, and exercise increases resilience to brain
aging and neurodegeneration through increases in brain
volume.31 This study highlighted the potential impor-
tance of a targeted exercise program in improving cogni-
tive functioning in men with prostate cancer.
Results from MAX-PC are somewhat difficult to
interpret. The MAX-PC anxiety scale is focused on anxi-
ety related to prostate-specific antigen scores, risk of recur-
rence, and generalized anxiety and may be more suitable
for observing changes over longer periods of time. The
follow-up of participants at 6 or 12 months, rather than
12 weeks, may provide a better understanding of the role
of exercise and its impact on anxiety.
Nearly half of the participants in the intervention
group indicated their intention to continue their program
by joining their local community gym; the majority
reported a benefit from the targeted program. Whether the
program is sustained over time will determine the potential
of the program to improve the medium- and long-term
health outcomes for men living with the disease.32
Exercise adherence can be a challenge in cancer tri-
als.33 However, this was not evident in the current study.
In comparison with the control arm, there was a higher
representation of patients who had surgery and completed
adjuvant therapies, including radiotherapy and androgen-
deprivation therapy, and participated in the intervention.
The program was well tolerated by participants; only 13%
completed fewer than 18 sessions, and this suggested that
the exercise program was acceptable to participants. Attri-
tion was substantially lower than that for other exercise tri-
als, which reported attrition rates ranging from 0% to
44%.33 This reduces the risk of bias in the current study.
The majority of the participants found the program
rewarding and reported that it was beneficial to their health
and well-being and that they achieved their exercise goals;
this suggests that it was feasible. Supervised programs
ensure that the exercise is targeted to the individual, and
this can reduce the risk of injury and improve adherence to
the program; the unsupervised home-based program
potentially increases long-term adoption and maintenance
of physical activity as part of one’s daily routine.33,34
Importantly, among those who agreed to participate,
80% reported that the clinician’s referral to take part in
the 12-week program influenced their decision to partici-
pate. This has important clinical implications for how
clinicians may assist and facilitate men’s physical activity
engagement in tailored exercise programs for improved
physical activity and health outcomes.35
Our trial’s strengths include recruitment of a sequen-
tial cohort of men with prostate cancer across public and
private outpatient clinics, clinicians providing a standar-
dized referral to men to a supervised exercise program, high
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adherence rates being achieved with the 2 gym sessions and
1 home-based session per week over the 12-week period,
the use of previously validated measures, and 95% partici-
pant compliance with questionnaire completion.
Limitations of the study include the fact that the av-
erage MVPA levels at the baseline were higher than those
found in the clinical trial from which we derived our ini-
tial power calculations,36 and this suggests that we may
have recruited a more physically active sample of partici-
pants. Response bias is difficult to overcome in a study
that relies on voluntary participation. Modest recruitment
and fixed-term funding constraints resulted in a sample of
147 participants rather than the original target of 200.19
A post hoc power analysis was conducted and showed that
there was 80% power to detect an interaction effect (time-
by-treatment group) of 80 minutes.
Differential intervention effects between self-report
and accelerometer data have been reported elsewhere in
other cancer cohorts.37 However, a recent systematic
review that compared self-reporting, including diaries,
and direct measurement results found no clear trends in
the overreporting or underreporting of physical activity
by self-reporting versus direct methods.38 Researchers
undertaking exercise studies should consider including
self-report exercise behavior as well as objective measure-
ments.32 We achieved a 46% participation rate, which
was better than, or similar to, the rates in other random-
ized controlled trials involving prostate cancer survi-
vors8,10,33; however, our sample was overrepresented by
men with stage I and II disease. Future research should
address different disease stages and exercise capacity in
these vulnerable disease groups.
Our trial highlighted that clinicians are ideally suited
to provide a teachable moment17 and refer men to exercise
programs as part of their clinical care after active treat-
ment for prostate cancer with an individually tailored
supervised program to improve quality-of-life outcomes.
Engagement with medical and allied health professionals
in the establishment of a clinician referral pathway for
exercise-based programs could reduce the barriers to exer-
cise among prostate cancer survivors. Further study is
required to determine the sustainability of the exercise
program and its generalizability to other disease stage
groups and cancer populations and investigate whether
the supervised 12 week program is better suited for men
who are more sedentary.10
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